Scott E. Deeter, Chief Executive Officer, and Mark Stathos, Ph.D., Director of Cell Biology, have published a scientific review examining what it will take to move an rVSV-vectored Bundibugyo ebolavirus vaccine from preclinical proof of concept into a product that survives manufacture, freezing, thaw, and delivery in the field. The review arrives during an urgent …
Recombinant albumin is the only stabilizing excipient in the licensed ERVEBO® vaccine — and the same formulation decisions are being made right now for Bundibugyo candidates. The filovirus virion: a fragile, host-cell-derived lipid bilayer studded with glycoprotein trimers — and the biophysical problem every rVSV-vectored vaccine formulation has to solve. Publication Details Publication Title: Translating …
Register Now Why Attend This Webinar? Understand how animal component-free rHSA can reduce variability and support more defined cell therapy manufacturing workflows. See how rHSA performs in iPSC, T cell, and MSC cryopreservation models, including post-thaw outcomes beyond viability. Learn how recombinant albumin compares with plasma-derived albumin in purity, consistency, and supply security. Get practical …
